IMPACT OF NEXTSENSE INSTITUTE RESEARCH IN THE FIELD OF SENSORY DISABILITIES
With
Professor Greg Leigh AO,
Director, NextSense Institute, Australia &
Conjoint Professor,
Macquarie School of Education
Macquarie University, Sydney
RESEARCH IMPACT
Filmed in Sydney, Australia | June 2025
NextSense, formerly known as the Royal Institute for Deaf & Blind Children, is a not-for-profit established in 1860 that provides dedicated, innovative, and customised services aimed at breaking down barriers for children, adults and families of people with hearing or vision loss.
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations.
The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
The Institute offers a range of educational programs, including postgraduate degrees, professional development courses, and customised training for educators, therapists, health professionals, and carers. One of its flagship programs is the Master of Disability Studies, delivered in affiliation with Macquarie University, which prepares professionals to work with individuals who are deaf, hard of hearing, blind, or have low vision.
Professor Greg Leigh AO, Director NextSense Institute, talks about 3 areas of research that have had significant impact in it’s delivery of programs and services to Australians and countries across the world.
Through this research, NextSense Institute aims to break down barriers and redefine what is possible for individuals with sensory disabilities, fostering inclusion and enhancing quality of life.
Source: Written by AUDIENCED using source information from the NextSense website
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.
